Neuropeptides in Alzheimer type dementia

Area of Science:

• Neuroscience
• Neuropathology
• Biochemistry

Background:

• Alzheimer-type dementia (ATD) is characterized by neuropathological changes and neurotransmitter system alterations.
• Investigating neuropeptide changes in ATD is crucial for understanding disease mechanisms.

Purpose of the Study:

• To measure levels of five neuropeptides (cholecystokinin, vasoactive intestinal polypeptide, somatostatin, neurotensin, and substance P) in various brain regions of individuals with and without ATD.
• To assess choline acetyltransferase (CAT) activity in relation to neuropeptide changes.

Main Methods:

• Neuropeptide levels were quantified in 14 brain areas from 12 ATD brains and 13 control brains.
• Choline acetyltransferase (CAT) activity was measured in 6 brain areas.
• Statistical analysis was performed to compare peptide levels and CAT activity between groups and identify correlations.

Main Results:

• Somatostatin (SRIF) levels were reduced in several cortical areas in ATD, but not in hippocampus, amygdala, thalamus, hypothalamus, or most striatal areas.
• SRIF reduction in ATD was less widespread and severe than CAT activity deficits.
• An increase in substance P (SP) was observed in the putamen, and altered NT and SRIF levels were found in the septum in ATD.

Conclusions:

• Somatostatin (SRIF) is the primary neuropeptide showing significant changes in Alzheimer-type dementia, mainly in cortical regions.
• These SRIF alterations do not uniformly mirror neuropathological changes or CAT deficits.
• The findings suggest a complex interplay of neurotransmitter and neuropeptide dysregulation in ATD.